AU2001255168A1 - Compositions and methods for the treatment of immune related diseases - Google Patents

Compositions and methods for the treatment of immune related diseases

Info

Publication number
AU2001255168A1
AU2001255168A1 AU2001255168A AU5516801A AU2001255168A1 AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1 AU 2001255168 A AU2001255168 A AU 2001255168A AU 5516801 A AU5516801 A AU 5516801A AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
related diseases
immune related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255168A
Inventor
Dan L Eaton
Sherman Fong
Audrey Goddard
Paul J Godowski
Christopher J. Grimaldi
Austin L. Gurney
Daniel Tumas
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001255168A1 publication Critical patent/AU2001255168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
AU2001255168A 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases Abandoned AU2001255168A1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US19101500P 2000-03-21 2000-03-21
US60/191,015 2000-03-21
PCT/US2000/014941 WO2000073348A2 (en) 1999-06-02 2000-05-30 Methods and compositions for inhibiting neoplastic cell growth
AU55911/00 2000-05-30
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU75730/00 2000-08-24
US60/000,000 2000-09-15
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU20554/01 2000-12-01
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
AU2001255168A1 true AU2001255168A1 (en) 2001-09-17

Family

ID=27485932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255168A Abandoned AU2001255168A1 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases

Country Status (2)

Country Link
AU (1) AU2001255168A1 (en)
WO (1) WO2001066740A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1191035A3 (en) * 2000-09-25 2002-04-17 Schering Aktiengesellschaft Three members of the cytokin-receptor class II family
WO2002066647A2 (en) 2001-01-12 2002-08-29 Genetics Institute, Llc. Type 2 ctokine receptor and nucleic acids encoding same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024908A1 (en) * 1996-12-05 1998-06-11 Human Genome Sciences, Inc. Human chemokine beta-13
WO2000078961A1 (en) * 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2001518793A (en) * 1997-04-10 2001-10-16 ジェネティックス・インスチチュート・インコーポレーテッド Secretory expression sequence tags (sESTs)
ATE338117T1 (en) * 1997-08-01 2006-09-15 Serono Genetics Inst Sa 5' ESTS FOR PROTEINS THAT ARE NOT TISSUE SPECIFIC
EP1029045A2 (en) * 1997-11-13 2000-08-23 Genset EXTENDED cDNAs FOR SECRETED PROTEINS
JP2002519000A (en) * 1998-01-28 2002-07-02 カイロン コーポレイション Human genes and gene expression products II
NZ531664A (en) * 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
CA2343696A1 (en) * 1998-09-25 2000-04-06 Incyte Pharmaceuticals, Inc. Membrane-associated organizational proteins
ES2287020T3 (en) * 1999-06-02 2007-12-16 Genentech, Inc. PROCEDURE AND COMPOSITIONS TO INHIBIT THE GROWTH OF NEOPLASSIC CELLS.
EP1067182A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
JP3951035B2 (en) * 1999-09-01 2007-08-01 ジェネンテック・インコーポレーテッド Secreted and transmembrane polypeptides and nucleic acids encoding them
CA2490853A1 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1252305A2 (en) * 1999-12-08 2002-10-30 Genset Full-length human cdnas encoding potentially secreted proteins

Also Published As

Publication number Publication date
WO2001066740A3 (en) 2002-09-19
WO2001066740A2 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IL145470A0 (en) Compositions for the treatment of immune diseases
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
EP1578373A4 (en) Novel compositions and methods for the treatment of immune related diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease